Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remibrutinib in generalized Myasthenia Gravis (CLOU064O12301)
jRCT2021250004Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Jul 2025
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in myasthenia gravis (MG) comparing Remibrutinib arm with Placebo arm (2 arms). Primary endpoint: Change from baseline to Month 6 in MG-ADL total score. Started Jul 2025; status: active, not recruiting.
02
Drugs
remibrutinib
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on jRCT2021250004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021250004.